ArticleAnnals of surgical oncology2026
Impact of Neoadjuvant Chemotherapy on Prognosis of Patients with Mucinous Gastric Adenocarcinoma: A Propensity Score Matching Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucinous gastric adenocarcinoma (MGC) is a rare, aggressive malignancy. This study aimed to explore whether MGC is associated with poorer survival compared with nonmucinous gastric adenocarcinoma (NMGC) and to further investigate the potential impact of neoadjuvant chemotherapy (NAC) on MGC by assessing overall survival (OS), tumor regression grade (TRG), and histological subtypes.
methodsA retrospective analysis was conducted on 492 patients with MGC and 7945 patients with NMGC undergoing resection at Zhejiang Cancer Hospital (2014-2023). Patients were categorized into neoadjuvant and surgery groups. MGC was further classified as pure (≥ 80%) or mixed (< 80%). OS was analyzed using Kaplan-Meier and Cox regression, with propensity score matching (PSM) for adjustment.
resultsAfter PSM, OS did not differ between MGC and NMGC. Patients with MGC receiving NAC had significantly worse OS than those undergoing surgery, with NAC as an independent risk factor. TRG analysis showed a markedly lower proportion of responders (TRG 0-1) in MGC than NMGC, indicating reduced chemosensitivity. Among subtypes, NAC remained an adverse factor in pure MGC, while mixed MGC showed no significant difference after PSM.
conclusionsMGC exhibits poor pathological response and no survival benefit from NAC, supporting upfront surgery as the preferred approach. TRG findings highlight intrinsic chemoresistance, particularly in pure MGC, underscoring the need for histology-based individualized strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.